BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Randomised clinical trial: effect of low-FODMAP rye bread versus regular rye bread on the intestinal microbiota of irritable bowel syndrome patients: association with individual symptom variation. ✅
Go to Publication ✅
BMC nutrition (BMC Nutr ) Vol: 5 Issue Pages: 12 Pub: 2019 Epub: 2019 Mar 6 Authors Laatikainen R , Jalanka J , Loponen J , Hongisto SM , Hillilä M , Koskenpato J , Korpela R , Salonen A , |
|
|
Randomised clinical trial: effect of low-FODMAP rye bread versus regular rye bread on the intestinal microbiota of irritable bowel syndrome patients: association with individual symptom variation. ✅
Go to Publication ✅
BMC nutrition (BMC Nutr ) Vol: 5 Issue Pages: 12 Pub: 2019 Epub: 2019 Mar 6 Authors Laatikainen R , Jalanka J , Loponen J , Hongisto SM , Hillilä M , Koskenpato J , Korpela R , Salonen A , |
|
|
Fecal microbiota composition affects in vitro fermentation of rye, oat, and wheat bread. ✅
Go to Publication ✅
Scientific reports (Sci Rep ) Vol: 13 Issue 1 Pages: 99 Pub: 2023 Jan 3 Epub: 2023 Jan 3 Authors Pirkola L , Dicksved J , Loponen J , Marklinder I , Andersson R , |
|
|
Prebiotic potential of wheat and dark rye: modulation of gut microbiota and short-chain fatty acid-producing bacteria. ✅
Go to Publication ✅
Food science and biotechnology (Food Sci Biotechnol ) Vol: 34 Issue 11 Pages: 2563-2570 Pub: 2025 Jul Epub: 2025 Apr 29 Authors Kim J , Kim J , Kim G , Kim S , Shin H , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
